- Plans in the works to save Esquire Theater on Broadway in Cape (2/21/18)2
- TJ's Burgers, Wings & Pizza expands with dining area in Fruitland (2/16/18)
- Pence gets it right in response to attack on Christian faith (2/17/18)6
- As February winds down, Chaffee looking forward to reopening of ice cream shop (2/21/18)1
- Scott City puts school on lockdown; officials say alleged threat 'not credible' (2/21/18)2
- The heart of the matter: Clinic helps patients rise above congestive heart failure (2/17/18)
- Jackson schools purchased former orchard land, will lease for farming for now (2/15/18)
FDA requires new labels on HRT products
WASHINGTON -- The government announced new warnings Wednesday on the labels for hormone replacement therapies and advised millions of post-menopausal women to consult their doctors about whether to continue treatment.
The Food and Drug Administration acted after reviewing data from a landmark study that found that the increased risk of heart disease and breast cancer from using therapies combining the hormones estrogen and progestin far outweighed any health benefits. The government abruptly halted that study last July.
The FDA approved new labels for Wyeth Pharmaceuticals that includes a new boxed warning highlighting the increased risk for heart disease, heart attacks, strokes and breast cancer. They also include a reference to the study findings.
The new labels also emphasize that these products are not approved for the prevention of heart disease.
The FDA also said it was asking all manufacturers of estrogen and estrogen-progestin products to add similar warnings and change the enclosed patient information leaflet because all hormone products are believed to carry similar health risks.